Tirzepatide 10mg — Vial Spec, Reconstitution Math & COA

Overview of Tirzepatide 10mg Lyophilized Vials

A 10mg vial of Tirzepatide provides ten milligrams of net active peptide cake, co-lyophilized with standard inert bulking agents to maximize physical stability during transport and cold storage. This specific mass threshold is widely selected by biomedical researchers, academic laboratories, and contract research organizations (CROs) managing multi-week rodent cohorts or running high-density in vitro signaling screens.

Choosing a 10mg vial mass allows laboratory staff to prepare larger batch volumes of working stock solution while reducing the unit-to-unit variability associated with reconstituting multiple smaller vials. If an exact 10mg vial configuration is temporarily undergoing inventory re-lotting or quality control re-certification, investigators can browse current catalog options within our comprehensive all research peptides inventory or evaluate equivalent mass configurations under our Tirzepatide research peptide product page.

Biochemical Structure and Dual-Agonist Mechanism

Tirzepatide is a synthetically engineered 39-amino-acid peptide analog modeled primarily on the native glucose-dependent insulinotropic polypeptide (GIP) sequence, modified with a C20 fatty diacid diacyl moiety conjugated to a lysine residue at position 20. This chemical lipidation grants the molecule extended plasma protein binding capacities, allowing for prolonged half-life profiles in preclinical model organisms.

In preclinical pharmacodynamic evaluations, Tirzepatide functions as an unbalanced dual receptor agonist. It exhibits equipotent affinity to native GIP at the GIP receptor, while demonstrating approximately five-fold lower affinity for the glucagon-like peptide-1 (GLP-1) receptor compared to endogenous GLP-1. In vitro cell assay models indicate that simultaneous activation of GIPR and GLP-1R triggers synergistic intracellular cyclic adenosine monophosphate (cAMP) signal transduction pathways, driving cellular cascades distinct from those activated by single-receptor GLP-1 agonists.

Reconstitution Mathematics: Diluent Volumes & Concentration Yields

Accurate volumetric reconstitution is essential to achieve predictable working concentrations for micro-pipetting into cell culture media or calculating dosage per kilogram in animal models. Reconstitution concentration ($C$) is calculated by dividing the total peptide mass ($m = 10\text{ mg}$) by the diluent volume ($V$).

To achieve target working stock concentrations with a 10mg vial, apply the following standard diluent ratios:

1.0 mL Diluent Yields: $10.0\text{ mg/mL}$ ($10.0\text{ }\mu\text{g/}\mu\text{L}$). Ideal for concentrated stock storage and low-volume micro-aliquoting.

2.0 mL Diluent Yields: $5.0\text{ mg/mL}$ ($5.0\text{ }\mu\text{g/}\mu\text{L}$). Offers a balanced concentration for intermediate pipetting precision.

3.0 mL Diluent Yields: $3.33\text{ mg/mL}$ ($3.33\text{ }\mu\text{g/}\mu\text{L}$). Well-suited for serial dilution preparation across extensive plate assays.

5.0 mL Diluent Yields: $2.0\text{ mg/mL}$ ($2.0\text{ }\mu\text{g/}\mu\text{L}$). Recommended when dispensing larger volumes into automated microplate handling systems.

For complex dilution schemes or custom volumetric calculations, investigators can utilize the interactive peptide reconstitution calculator to determine exact liquid draw volumes prior to protocol execution.

Aliquot Planning and Laboratory Pipetting Protocols

Repeated freeze-thaw cycles subject peptide chains to mechanical shear stress and temperature fluctuations, leading to structural precipitation or peptide aggregation. To preserve structural integrity, laboratory staff should perform reconstitution inside a laminar flow cabinet utilizing sterile technique.

Reconstitution fluid—typically Bacteriostatic Water (0.9% benzyl alcohol) or Sterile Normal Saline—should be directed slowly against the interior glass wall of the vial rather than sprayed directly onto the lyophilized cake. Allow the vial to sit undisturbed for 5 to 10 minutes at ambient room temperature, followed by gentle side-to-side swirling. Never vortex or vigorously shake peptide solutions, as air-water interfaces induce peptide denaturation.

Once fully dissolved, divide the working stock solution into sterile, polypropylene low-binding microcentrifuge tubes in single-use aliquot volumes. Label each tube with the reconstitution date, concentration, and batch lot number before placing them in cryogenic storage.

Analytical Validation: HPLC, LC-MS, and Lot-Matched COAs

Every production lot of Tirzepatide processed by PX1 Research undergoes rigorous testing to verify purity, chemical identity, and biological safety. Quality assurance protocols leverage High-Performance Liquid Chromatography (HPLC) to confirm chromatographic purity greater than 99%, ensuring that no truncated peptide sequences or chemical impurities compromise assay data.

Electrospray Ionization Liquid Chromatography-Mass Spectrometry (LC-MS) confirms the precise target molecular mass of 4813.5 Da. Additionally, end-product testing includes Chromogenic Limulus Amebocyte Lysate (LAL) assays to enforce strict endotoxin boundaries below 0.01 EU/mg, preventing endotoxin-induced inflammatory artifacts in cellular or animal studies.

Every vial shipped is tied to a lot-specific Certificate of Analysis. Laboratory directors and procurement officers can independently verify analytical chromatograms and mass spectra by visiting our open-access COA verification hub.

Comparative Analysis: Incretin Mimetic Research Compounds

When designing metabolic pathways research, selecting the appropriate incretin class compound depends heavily on receptor selectivity profiles. Tirzepatide represents a dual-agonist framework, contrasting both single-target GLP-1 compounds and multi-target triple-agonist molecules.

In head-to-head rodent models, single-target agonists such as Semaglutide and Liraglutide operate exclusively through GLP-1 receptor pathways, driving distinct glucose-stimulated insulin release without concurrent GIP activation. Conversely, next-generation triple agonists such as Retatrutide activate GIP, GLP-1, and glucagon (GCG) receptors simultaneously, altering hepatic lipid flux to a degree beyond dual-agonist capabilities.

Comparative in vitro screens consistently demonstrate that dual GIP/GLP-1 co-agonism provides a unique signaling baseline, making Tirzepatide 10mg vials an essential reference standard for dissecting dual-pathway synergy.

Vial Format Selection: Evaluating 10mg vs. Alternate Mass Sizes

Selecting the correct vial size is critical for minimizing wasted reagent and maintaining consistent experimental timelines. The 10mg format offers an optimal balance between unit yield and open-vial shelf-life management.

Smaller vial sizes (such as 2mg or 5mg) are generally preferred for pilot feasibility studies or short-duration in vitro experiments where reconstituted solution will be exhausted within 24 to 48 hours. Conversely, larger mass formats (such as 15mg or 30mg) offer cost efficiencies for high-throughput robotic screening platforms.

The 10mg vial serves as the standard workhorse format for chronic animal study designs spanning 14 to 28 days, allowing investigators to prepare unified reconstituted batches that reduce inter-dose concentration drift.

Storage, Stability, and Degradation Kinetics

Unreconstituted lyophilized Tirzepatide 10mg vials must be stored in a sub-zero freezer environment between -20°C and -80°C, protected from ambient light exposure and moisture. Under these conditions, the desiccated powder maintains stability and chromatographic purity for up to 24 months from the manufacturing date.

Once reconstituted with bacteriostatic solvent, liquid solutions must be kept refrigerated at 2°C to 8°C. Reconstituted solutions maintained with 0.9% benzyl alcohol remain stable for up to 28 days under strict cold-chain handling. Reconstituted peptide stored without antimicrobial preservatives must be used immediately or discarded after single-use procedures to prevent bacterial contamination.

PX1 Research Supply Chain & Quality Assurances

PX1 Research operates dedicated manufacturing and distribution operations within the United States, utilizing GMP-aligned facilities and ISO 17025 accredited analytical laboratories. All catalog compounds undergo rigorous independent quality testing to guarantee that research facilities receive highest-tier reference materials.

Orders dispatch directly from state-of-the-art fulfillment facilities located in California and Arizona. Orders placed Monday through Friday prior to standard carrier cutoffs ship the same day, protecting thermal integrity and ensuring rapid transit.

For large-scale academic grants, contract studies, or institutional research programs requiring dedicated lot reservations, procurement teams are encouraged to explore our flexible PX1 wholesale program or review scientific documentation via our centralized peptide research index.